Document:

<PAGE>   1
                                                                    Exhibit 10.3

                          LICENSE AND SUPPLY AGREEMENT

         This License and Supply Agreement (the "Agreement"), effective as of
April 5, 1999 (the "Effective Date"), is made by and between Molecular Probes,
Inc., an Oregon corporation, ("MPI") and Cellomics(TM), Inc., a Delaware
corporation ("CI").

                                   BACKGROUND

         A.       CI has developed a cell based screening system for the
                  analysis of cellular biochemical and molecular parameters
                  through combinatorial cell biology; and

         B.       MPI has expertise in the development and manufacture of
                  certain proprietary and non-proprietary fluorescence based
                  reagents; and

         C.       CI desires to obtain from MPI and MPI desires to grant CI
                  certain licenses to use MPI's proprietary fluorescence based
                  reagents; and

         D.       The parties desire that CI purchase and MPI supply certain
                  proprietary and non-proprietary products on the terms and
                  conditions set forth below.

NOW, THEREFORE, for and in consideration of the mutual covenants and promises
herein contained, the parties hereto agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

         1.1 "CI Specifications" shall mean collectively (i) the quality control
standards, as amended from time to time, that materials supplied to CI must meet
for use under this Agreement; and (ii) the packaging protocols required by CI,
as amended from time to time, for materials supplied for use under this
Agreement.

         1.2 "Confidential Information" shall have the meaning as set forth in
Section 8.1 below.

         1.3 "Custom Product" shall mean a Licensed Material or a
Non-Proprietary Material that is not available from MPI as a Stock Item, but is
available by special request, e.g. to obtain a material that has the same
chemical formula as a Stock Item but has different quality control
specifications or special packaging requirements, or a material with a chemical
composition that is not offered as a Stock Item. For purposes of this Agreement,
consolidated packaging of bulk amounts of Stock Items are not Custom Products.

         1.4 "Field" shall mean   [*]  .

         1.5 "Finished Product(s)" shall mean any kit incorporating Licensed
Materials that is transferred by CI, in return for compensation, to a third
party for use in the Field, where the kit, or the Licensed Materials in such
kit, or the use thereof, is covered by a Valid Claim.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               1
<PAGE>   2

         1.6 "High Content Screening" or ("HCS") shall mean [*]  .

         1.7 "Licensed Material(s)" shall mean (i) any chemical or biochemical
composition(s), including Proprietary Material(s), that are covered by a Valid
Claim or, (ii) where the composition itself is not covered by a Valid Claim, its
use is covered by a Valid Claim and its manufacture is a trade secret of MPI.
Licensed Materials include, but are not limited to,  [*]  . Not all Licensed
Materials are Proprietary Materials  [*]  .

         1.8 "MPI Technology Package" shall mean the groupings of MPI Patents
that are designated in Exhibits A and B, and the corresponding MPI Technical
Information.

                  1.8.1 "MPI Patents" shall mean any issued patents or patent
applications that are identified as "Licensed Patents" on Exhibits A and B, as
amended from time to time, and all corresponding patents issuing from such
applications, and all reissues, renewals, re-examinations, and extensions
thereof, and any divisions or continuations (in whole or in part) thereof, and
any foreign equivalents thereof, as amended from time to time by the agreement
of the parties,  [*]  .

                  1.8.2 "MPI Technical Information" shall mean confidential
information, tangible or intangible, and materials, including but not limited
to: pharmaceutical, chemical, biological, genetic and biochemical compositions;
and technical and non-technical data and information, and/or the results of
tests, assays, methods and processes; and plans, specifications and/or other
documents containing said information and data; in each case that is possessed
by MPI as of the Effective Date or during the Term, to the extent such relates
to the manufacture of Licensed Materials, including Proprietary Materials, of a
given MPI Technology Package.

         1.9 "Net Sales" shall mean the gross amounts received by CI for the
Sale of Finished Products or Services, less the following amounts directly
chargeable to such Finished Products or

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               2
<PAGE>   3

Services: (a) customary trade, quantity or cash discounts and rebates, actually
allowed and taken; (b) amounts repaid or credited to customers on account of
rejections; (c) freight and other transportation costs, including insurance
charges, and duties, tariffs, sales and excise taxes and other governmental
charges based directly on Sales, turnover or delivery of such Finished Products
or Services and actually paid or allowed by CI; and (d) amounts allowed or
credited due to returns or uncollectible amounts. Where Finished Materials or
Services are Sold to third parties for compensation other than cash, Net Sales
shall mean the cash equivalent of the fair market value of such other
compensation.

         1.10 "Non-Proprietary Materials" shall mean any non-proprietary
materials set forth on Exhibit C attached hereto produced by MPI and purchased
by CI pursuant to this Agreement.

         1.11 "Proprietary Materials" shall mean those materials set forth in
Exhibits A and B attached hereto, as amended from time to time, under the column
entitled "Proprietary Materials".

         1.12 "Sell", including any variations of the verb "to Sell" or the noun
"Sale" means to transfer to a third party in return for compensation, whether
such compensation is in the form of cash payment or in the form of a transfer of
a non-cash, tangible or intangible asset.

         1.13 "Services" shall mean any services conducted by CI in the Field
and covered by a Valid Claim.

         1.14 "Stock Item(s)" shall mean any material that is commercially
available from MPI and is identified with a specific product number on MPI's
website (www.probes.com) or in MPI's publications.

         1.15 "Ultra High-Throughput Screening" or ("UHTS") shall mean  [*]  .

         1.16 "Valid Claim" shall mean a written claim filed as part of any
unexpired patent application or issued patent within the MPI Patents that has
not been held unenforceable, unpatentable or invalid by a decision of a court or
governmental body of competent jurisdiction in a ruling that is unappealable or
unappealed within the time allowed for appeal, and that has not been rendered
unenforceable through disclaimer or otherwise, and that has not been lost
through an interference proceeding. In the event that the relevant MPI Patent is
a provisional patent application that does not include any claims, any specific
embodiment that is described in such provisional application shall be deemed to
be covered by a Valid Claim until such time as a corresponding utility
application is filed that contains one or more claims or such provisional
application expires without the filing of a corresponding utility application
that contains one or more claims, whichever is sooner.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               3

<PAGE>   4

                                    ARTICLE 2
                                    LICENSES

         2.1 Non-exclusive License to CI to Make or Have Made Licensed
Materials. Subject to the terms and conditions of this Agreement, MPI hereby
grants to CI a non-exclusive license under the MPI Technology Packages, to make
or have made Licensed Materials in accordance with the provisions of Article 5
below. CI is not authorized to Sell Licensed Materials except in Finished
Product(s) or in Services.

         2.2 Exclusive License to CI for Use with HCS. Subject to the terms and
conditions of this Agreement, and in accordance with the specific limitations of
this Section 2.2 (including the subsections below), MPI hereby grants to CI
certain worldwide, exclusive rights under each MPI Technology Package listed in
Exhibit A, for use in the Field, where such rights are exclusive solely for use
with HCS.

                  2.2.1 MPI hereby grants to CI an exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to Sell or offer for
Sale Licensed Materials as part of Finished Products to third parties for use
with HCS.

                  2.2.2 MPI hereby grants to CI an exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to import or export
Finished Products for use with HCS.

                  2.2.3 MPI hereby grants to CI an exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to use Licensed
Materials with HCS in Services that are Sold or offered for Sale to third
parties.

                  2.2.4 In the event that CI is unable to (i) commercialize the
use of a given MPI Technology Package within three years after the Effective
Date, and (ii) generate royalties of  [*]  per year from such MPI Technology
Package within five years after the Effective Date, the exclusive license
granted to CI pursuant to this Section 2.2 shall become non-exclusive with
respect to that MPI Technology Package only, and the provisions of Sections
3.2.2 and 3.5 shall apply.

         2.3 Non-Exclusive License to CI for Use with UHTS. Subject to the terms
and conditions of this Agreement, and in accordance with the specific
limitations of this Section 2.3 (including the subsections below), MPI hereby
grants to CI certain worldwide, non-exclusive rights under each MPI Technology
Package listed in Exhibit A, for use in the Field, where such rights are solely
for use in UHTS.

                  2.3.1 MPI hereby grants to CI a non-exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to Sell or offer for
Sale Licensed Materials as part of Finished Products to third parties for use
with UHTS.

                  2.3.2 MPI hereby grants to CI a non-exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to import or export
Finished Products for use with UHTS.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               4
<PAGE>   5

                  2.3.3 MPI hereby grants to CI a non-exclusive, world-wide,
royalty bearing license under the MPI Technology Packages to use Licensed
Materials with UHTS in Services that are Sold or offered for Sale to third
parties.

         2.4 Right of First Refusal to Obtain an Exclusive License for Use in
HCS. MPI hereby grants to CI a right of first refusal ("Option"), commencing on
the Effective Date and expiring on the first anniversary thereafter ("Option
Period"), to obtain an exclusive, worldwide, royalty-bearing license under the
MPI Technology Packages listed in Exhibit B to make, have made, Sell, offer for
Sale, import, export or use Licensed Materials solely for use in HCS, in
accordance with the rights and limitations in Sections 2.1 and 2.2 above; and a
non-exclusive, worldwide, royalty-bearing license under the MPI Technology
Packages listed in Exhibit B to make, have made, Sell, offer for Sale, import,
export or use Licensed Materials solely for use in UHTS, in accordance with the
rights and limitations in Sections 2.1 and 2.3 above. Whether to exercise such
Option is solely at the discretion of CI, but CI must exercise its Option by
payment of the license fee, as described in Section 3.8, for the desired
additional MPI Technology Packages before the expiration of the Option Period.
Upon payment of the corresponding license fee(s) set forth in Section 3.8, the
same rights granted in Sections 2.1 through 2.3 covering the use of the MPI
Technology Packages in Exhibit A shall be extended automatically to cover the
use of the corresponding MPI Technology Package(s) in Exhibit B.

         2.5 Option to Add Subsequent MPI Technology Packages to Exhibit A and
Exhibit B. CI and MPI agree to negotiate in good faith the terms under which CI
shall, from time to time, add subsequent MPI Technology Packages to Exhibit A
and Exhibit B. In particular, CI shall have a right of first refusal for use and
Sale in the Field  [*]  . The parties anticipate the annual license fees for
each individual MPI Technology Package added hereunder shall approximate the
license fee (described in Section 3.8) for the addition of MPI Technology
Packages pursuant to Section 2.4 above.

         2.6 Termination of Rights Under Technology Packages. CI may terminate
its obligations to pay to MPI any Annual Minimum Royalty payments and royalties
under any particular MPI Technology Package by notifying MPI in writing of such
intent before the next Annual Minimum Royalty payment is due pursuant to Section
3.2, and concurrently terminating all activities described under Sections 2.1,
2.2 and 2.3 above, with respect to such MPI Technology Package.

         2.7 Exchange of Exclusive License for Non-Exclusive License. CI may
elect to change the exclusive license under a given MPI Technology Package
granted pursuant to Section 2.2, to a non-exclusive license under such MPI
Technology Package by notifying MPI in writing of such intent before the next
Annual Minimum Royalty payment is due pursuant to Section 3.2. In the event of
such an election by CI, the provisions of Section 3.2.2 and 3.5 shall apply.

         2.8 No Implied Licenses. Nothing herein shall be construed as granting
to either party, by implication, estoppel or otherwise, any license or other
right to any intellectual property of the other party other than those expressly
granted herein.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               5
<PAGE>   6

                                    ARTICLE 3
                           COMPENSATION AND ROYALTIES

         3.1 License Fee. In consideration of rights granted under Sections 2.1
through 2.3, and Section 2.5, CI shall pay to MPI a total license fee ("License
Fee") of $90,000 for the six MPI Technology Packages set forth on Exhibit A
hereto.

                  3.1.1 The License Fee shall be paid pursuant to the following
payment schedule:

                             [*]

                  3.1.2 From the License Fee paid to MPI pursuant to this
Section 3.1,  [*]  per MPI Technology Package shall be creditable against any
royalty payments for that MPI Technology Package that become due from the
Effective Date until April 1, 2000.

         3.2 Annual Minimum Royalty Payment. Beginning on April 1 of 2000 and
each subsequent anniversary thereof, CI shall pay to MPI an annual minimum
royalty ("Annual Minimum Royalty") for each MPI Technology Package in the
amounts described below, which Annual Minimum Royalty shall be creditable
against any royalties due on the corresponding MPI Technology Package during the
subsequent twelve month period following the previous Annual Minimum Royalty
payment:

                  3.2.1 For each MPI Technology Package under which CI wishes to
maintain exclusive rights pursuant to Section 2.2, as well as non-exclusive
rights pursuant to Sections 2.1 and 2.3, CI shall pay MPI an Annual Minimum
Royalty of  [*]  ;

                  3.2.2 For each MPI Technology Package in which CI wishes to
maintain non-exclusive rights pursuant to Sections 2.2.4 or 2.7, as well as
non-exclusive rights pursuant to Sections 2.1 and 2.3, the Annual Minimum
Royalty for that MPI Technology Package due to MPI by CI shall be reduced to
[*]  .

         3.3 Royalties on Services. Subject to the provisions of Section 3.5, CI
shall pay to MPI the following royalty rates for Services:

         3.3.1 For Services licensed under 2.2.3, a royalty of  [*]  in which
Licensed Material from any MPI Technology Package is used. If more than one
Licensed Material is simultaneously used  [*]  for such Services, whether from
the same MPI Technology Package or a different MPI Technology Package, CI would
pay an additional royalty of  [*]  for each additional Licensed Material used;
and

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               6
<PAGE>   7
         3.3.2 For Services licensed under 2.3.3, a royalty of  [*]  received by
CI for Services in which any Licensed Material from any MPI Technology Package
is used for UHTS.

         3.4 Royalties on Finished Products. Subject to the provisions of
Section 3.5, CI shall pay to MPI the following royalty rates for Finished
Products:

         3.4.1 a royalty of  [*]  of Net Sales of Finished Products sold for use
with HCS; and

         3.4.2 a royalty of  [*]  of Net Sales of Finished Products sold for use
with UHTS.

         3.5 Reduced Royalties from Change in Exclusivity. In the event that
exclusive rights under a given MPI Technology Package for use with HCS become
non-exclusive rights pursuant to Section 2.2.4 or 2.7, CI shall pay to MPI, in
lieu of any other royalty payments, the following royalty rates:

         3.5.1 a royalty of  [*]  of Net Sales of Finished Products sold for use
with HCS; and

                  3.5.2 a royalty for Services utilizing HCS that shall be
negotiated in good faith.

         3.6 Additional Royalties from Manufacture of Licensed Materials. In the
event that CI shall make or have made Licensed Materials for use in Services or
Finished Products pursuant to Sections 5.1.6, 5.1.8 or 5.1.9, instead of
obtaining such Licensed Materials from MPI, then CI shall pay to MPI the
following royalty rates, in addition to the royalty rates under Sections 3.2,
3.3, 3.4 or 3.5:

         3.6.1 for Services licensed under 2.2.3, an additional royalty of  [*]
for each such Licensed Material used for HCS;

         3.6.2 for Services licensed under 2.3.3, an additional royalty of  [*]
received by CI for Services in which any Licensed Material from any MPI
Technology Package is used for UHTS;

         3.6.3 for Finished Products sold for use with HCS or UHTS and that
incorporate such Licensed Materials, an additional royalty of  [*]  of Net Sales
of such Finished Products.

         3.7 Option Fee. CI shall pay to MPI a non-refundable option fee of  [*]
for each MPI Technology Package set forth on Exhibit B ("Option Fee"), which
Option Fee shall be due upon the Effective Date and shall be fully creditable
against any subsequent license fee (as described in Section 3.8) for such MPI
Technology Package upon exercise of the Option.

         3.8 License Fee for Additional MPI Technology Packages. To exercise its
Option pursuant to Section 2.4 above, CI shall pay MPI a license fee for each
individual MPI Technology Package added hereunder that approximates  [*]  for
the first year (subject to the credit applied under Section 3.7 above), after
which time the Annual Minimum Royalty of Section 3.2 would apply.

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                               7
<PAGE>   8

                                    ARTICLE 4
                           PAYMENTS; BOOKS AND RECORDS

         4.1 Payment Terms and Method. Unless otherwise specified herein, all
payments hereunder shall be calculated on a quarterly basis from the Effective
Date and shall be due and payable sixty (60) days after. All dollar amounts
specified in this Agreement, and all payments made hereunder, are and shall be
made in U.S. dollars. If any payments are based on Net Sales denominated in
other than U.S. dollars, the conversion to U.S. dollars shall be the same
internal method CI uses to convert any other Sales denominations to U.S.
dollars, which internal method shall be in accordance with generally accepted
accounting principles.

         4.2 Any payments due under this Agreement which are not paid by the
date such payments are due under this Agreement shall bear interest to the
extent permitted by applicable law at the U.S. prime rate per annum quoted in
the "Money Rates" column of The Wall Street Journal (U.S., Western Edition) on
the first business day after such payment is due. This Section 4.2 shall in no
way limit any other remedies available to either party.

         4.3 Records. CI shall keep, complete, true and accurate books of
accounts and records for the purpose of determining the amounts payable pursuant
to this Agreement. Such books and records shall be kept for at least three (3)
years following the end of the calendar quarter to which they pertain. Such
records will be open for inspection at CI's principal place of business during
such three (3)-year period by an independent auditor chosen by MPI and
reasonably acceptable to CI for the purpose of verifying the amounts payable by
CI hereunder. Such inspections may be made no more than once each calendar year,
at reasonable times and on reasonable notice. The independent auditor shall be
obligated to execute a reasonable confidentiality agreement prior to commencing
any such inspection. Inspections conducted under this Section 4.3 shall be at
the expense of MPI, unless a variation or error producing an underpayment in
amounts payable exceeding ten percent (10%) of the amount paid for the period
covered by the inspection is established in the course of any such inspection,
whereupon all costs relating to the inspection for such period and any unpaid
amounts that are discovered shall be paid by CI, together with interest on such
unpaid amounts at the rate set forth in Section 4.2 above. The parties will
endeavor to minimize disruption of CI's normal business activities to the extent
reasonably practicable.

                                    ARTICLE 5
                             MANUFACTURE AND SUPPLY

         5.1 Exclusive Supplier of Licensed Materials. Except as expressly
provided in Sections 5.1.6, 5.1.8 or 5.1.9, MPI shall be the exclusive supplier
of all Licensed Materials.

                  5.1.1 Licensed Materials that are available from MPI as Stock
Items shall be manufactured to conform to MPI's internal specifications for
research grade reagents and packaged according MPI's internal packaging
protocols.

                  5.1.2 In the event that CI believes that such Stock Items do
not meet CI Specifications (including, e.g. where CI desires a chemical
composition that is not available as a Stock Item) CI shall notify MPI of such
CI Specifications. If such Licensed Materials are dye

                                                                               8
<PAGE>   9

conjugates of biomolecules, and the biomolecule is the basis for such Licensed
Materials not meeting CI Specifications (e.g. because CI desires a biomolecule
of a different class, or a different purity, etc.), then CI shall also identify
the nature of the desired biomolecule.

                  5.1.3 If CI desires to keep the identity of the desired
Licensed Material secret, CI shall indicate the confidential nature of its
communication, and MPI shall indicate the terms and conditions, if any, under
which such Licensed Material could be made available exclusively to CI as a
Custom Product and such Custom Product would not be made a Stock Item.

                  5.1.4 Within fifteen (15) days of CI's notification that
original Stock Items do not meet CI Specifications, MPI shall notify CI whether
or not MPI waives its right under Section 5.1 to exclusively manufacture a
Licensed Material that meets such CI Specifications.

                  5.1.5 If MPI does not waive its exclusive manufacturing right
for such specified Licensed Material at issue, MPI shall (concurrently with
MPI's notification to CI pursuant to Section 5.1.4) provide CI with a firm
quotation (including both price and delivery schedule) for such Licensed
Materials meeting such CI Specifications, and addressing all concerns under
Sections 5.1.3 and 5.2.5.

                  5.1.6 If the Licensed Material is not a Proprietary Material
and CI elects not to accept MPI's quotation, CI may make or have made the
Licensed Material for use in accordance with Article 2, subject to the
provisions of Sections 3.6, 6.2 and 6.5.

                  5.1.7 In the event that such Stock Items that do not meet CI
Specifications pursuant to this Section 5.1 are Proprietary Materials, CI may
request that such Proprietary Materials be supplied as a Custom Product, which
will be supplied at prices to be negotiated in good faith, and taking into
account all concerns under Sections 5.1.3 and 5.2.5.

                  5.1.8 In the event that MPI waives its rights to exclusively
manufacture a specific Licensed Material, CI shall have the right to make or
have made such Licensed Material for use in accordance with Article 2, subject
to the provisions of Sections 3.6, 6.2 and 6.5.

                  5.1.9 Notwithstanding the provisions of Section 11.2, CI shall
have the right to make or have made a given Proprietary Material, subject to the
provisions of Section 3.6, 6.2 and 6.5 in the event that:

                           (i) MPI fails to deliver such Proprietary Material as
stated on any CI firm purchase order, where such order for Proprietary
Material(s) conforms to the terms and conditions of this Agreement with respect
to:

                                    (a)      the price to be paid for such
                                             Proprietary Material;

                                    (b)      the amount of Proprietary Material
                                             to be delivered;

                                    (c)      the time frame for delivery of the
                                             Proprietary Material;

                                    (d)      the time frame for delivery of
                                             payment for Proprietary Material;

                                    (e)      the specifications for the
                                             Proprietary Material; and

                                    (f)      the location of the delivery of
                                             Proprietary Material;

                                                                               9
<PAGE>   10

and MPI fails to correct such failure within sixty (60) days of a written notice
of deficiency from CI, provided CI is not in default under any other provision
of this Agreement; or

                           (ii) MPI is declared insolvent pursuant to Section
365(n)(1) of the Bankruptcy Code or any similar provision of any controlling
state insolvency law(s);

until such time as MPI resumes manufacturing of such Proprietary Materials in
quantities sufficient to supply CI with Proprietary Materials consistent with
the terms and conditions set forth in this Agreement, and MPI notifies CI that
MPI is prepared to resume exclusive manufacture of such Proprietary Materials.

                  5.1.10 In the event that the provisions of Section 5.1.9
apply, MPI shall transfer to CI that documentation possessed by MPI that would
be reasonably necessary for a person with a Bachelor of Science degree in
organic chemistry and reasonably skilled in the relevant manufacturing and/or
analytical processes, to reproduce and manufacture the Proprietary Material(s)
previously available from MPI under the terms of this Agreement, including
without limitation, lists of raw materials, and their commercial sources,
synthesis and purification protocols, and methods and procedures for the
characterization and quality control. To the extent such documentation contains
Confidential Information of MPI, CI shall institute reasonable measures to
prevent its unauthorized use and/or disclosure.

         5.2 Supply. Subject to the terms and conditions of Section 5.1 and this
Section 5.2, MPI shall manufacture Licensed Materials in accordance with CI
Specifications, and shall supply CI with CI's requirements for Licensed
Materials. At CI's request, MPI shall also supply CI with Non-Proprietary
Material(s) subject to Sections 5.2.4, 5.2.5 and 5.5 (i) non-exclusively as
Stock Item(s) or (ii) exclusively as a Custom Product(s) or non-exclusively,
pursuant to Section 5.2.5, at CI's option. CI shall have the right to repackage
Licensed Materials (subject to the terms and conditions of Sections 2.1-2.3, 6.2
and 6.5), and Non-Proprietary Materials supplied by MPI hereunder

                  5.2.1 Forecasts. For so long as MPI is supplying Licensed
Materials to CI hereunder, at least thirty (30) days prior to the start of any
calendar quarter ("Q1"), CI shall provide MPI with a rolling written forecast of
the quantities of Licensed Materials (on a product-by-product basis) estimated
to be required on a quarter-by-quarter basis for four (4) consecutive quarters
("Q1" to "Q4", respectively). Each forecast shall indicate the estimated
quantities of Licensed Materials. CI will provide such forecasts as a means of
production planning only and such forecasts shall not constitute a binding
obligation upon MPI or CI. CI may also provide forecasts of its estimated
requirements for Non-Proprietary Materials, at its option, if CI desires such
estimates to be included in MPI's production planning for the purposes of
extending the provisions of Sections 5.2.3 to such Non-Proprietary Materials.

                  5.2.2 Form of Order. CI's orders shall be made pursuant to a
written purchase order which is in a form mutually acceptable to the parties.
MPI shall use reasonable efforts to notify CI within ten (10) days from receipt
of an order of its ability to fill quantities ordered thereunder, subject to
Section 5.2.3 below.

                                                                              10
<PAGE>   11

                  5.2.3 Shipping. All Licensed Materials and Non-Proprietary
Materials delivered pursuant to the terms of this Section 5.2 shall be suitably
packed for shipment by MPI, marked for shipment to the destination point
indicated in CI's purchase order. Unless otherwise agreed between the parties in
writing, orders for less than twenty-five (25) units of the same Stock Item for
which MPI has previously received a forecast pursuant to Section 5.2.1 shall be
shipped to CI within five (5) business days of receipt of the order; orders for
twenty-five (25) units or more of the same Stock Item shall be shipped within
thirty (30) days of receipt of the order. The shipment schedules for orders of
Custom Products will be determined at the time such order is placed, in
accordance with MPI's standard completion schedules for custom synthesis. All
Licensed Materials and Non-Proprietary Materials shipped to CI will be
delivered FOB (U.C.C.) the shipping point. All shipping and insurance costs, as
well as any special packaging expenses, shall be paid by CI.

                  5.2.4 Prices. MPI shall provide to CI all Licensed Materials
and Non-Proprietary Materials to CI for use in Finished Products and Services as
follows:

                           (i) MPI shall provide Stock Items at MPI's standard
retail rates as set forth in MPI's website for the period in which the purchase
order was submitted. CI shall be entitled to any standard quantity discounts MPI
offers to industry customers  [*]  .

                           (ii) In addition to the discount set forth above, CI
shall receive an additional discount rebate within thirty (30) days after the
conclusion of a semi-annual period, for aggregate purchases of Licensed
Materials and Non-Proprietary Materials that are Stock Items from the attached
MPI Technology Packages according to the following schedule:

                                    (1) for aggregate annual purchases of less
than  [*]  no discount rebate, regardless of the amount purchased;

                                    (2) for aggregate annual purchases of at
least  [*] ; a discount rebate that is  [*]  of such annual aggregate purchases
within the specified range;

                                    (3) for aggregate annual purchases of at
least  [*]  a discount rebate that is  [*]  of such annual aggregate purchases
within the specified range;

                                    (4) for aggregate annual purchases of at
least  [*]  ; a discount rebate that is  [*]  of such annual aggregate purchases
within the specified range.

                           (iii) MPI shall provide Custom Products at prices to
be negotiated in good faith, subject to Sections 5.1.3, 5.1.5, 5.1.7 and 5.2.5.
Prior to determination of the price to be paid for such Custom Product, MPI and
CI shall agree on the degree of exclusivity (pursuant to Section 5.2.5) as well
as the quality control specifications and packaging specifications for such
Custom Product, which agreed specifications shall become the CI Specifications
for such Custom Product, and in the event such Custom Product shall become a
Stock Item, subject to Sections 5.1.3 and 5.2.5, for such Stock Item. Such
Custom Products shall not be included in the annual aggregate purchases

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                              11
<PAGE>   12

that qualify for the discount rebate, unless and until such Custom Products
shall become available as Stock Items.

                  5.2.5 Prior to MPI accepting an order for a Custom Product, CI
and MPI shall agree in writing whether MPI may convert such Custom Product into
a Stock Item or produce it as a custom product for other party/ies, without
further approval from CI, to address CI's concerns about preserving CI's trade
secrets and MPI's concerns about maintaining flexibility in offering MPI's
technology to third parties for uses other than those exclusively licensed to
CI.

                  5.2.6 Invoicing and Payment. MPI shall submit an invoice to CI
upon shipment of Licensed Materials and Non-Proprietary Materials ordered by CI.
All invoices shall be sent to CI's address for notices hereunder and marked
"Attention: Accounting Department." Each such invoice shall state CI's aggregate
price therefor in a given shipment, plus any insurance, taxes or other costs
incident to the purchase or shipment initially paid by MPI but to be borne by CI
hereunder. Payment shall be made within thirty (30) days after the invoice is
sent to CI.

         5.3 Product Acceptance/Returns.

                  5.3.1 Unless agreed otherwise in writing prior to or
concurrently with acceptance of an order in accordance with Section 5.2.2, any
Licensed Materials and Non-Proprietary Materials supplied hereunder shall
conform at the time of shipment to MPI's internal specifications for research
grade reagents and packaged according MPI's internal packaging protocols.

                  5.3.2 Unless agreed otherwise in writing prior to or
concurrently with acceptance of an order in accordance with Section 5.2.2, any
Custom Products supplied hereunder shall conform at the time of shipment to CI
Specifications.

                  5.3.3 The parameters for evaluating the performance of
Licensed Materials in a particular application undertaken by CI are beyond the
control of MPI and, while such parameters may determine the suitability of
materials for such application, such parameters shall not be used to determine
acceptance of materials. Only written specifications agreed to between the
parties shall be used to determine acceptance of materials supplied by MPI.

                  5.3.4 Each shipment of Licensed Materials and Non-Proprietary
Materials hereunder shall be accompanied by a certificate of analysis for each
lot therein as well as such customs and other documentation as is necessary or
appropriate for shipment of materials from MPI to CI.

                  5.3.5 MPI will provide, upon CI's request, those test
procedures and test data that are the basis for the certificate of analysis
pertaining to Licensed Materials and Non-Proprietary Materials.

                  5.3.6 Without limiting the foregoing, if any Licensed
Materials or Non-Proprietary Materials supplied hereunder fail to conform to the
applicable CI Specifications or certificate of analysis, then CI shall promptly
notify MPI and present reasonable evidence to MPI of such nonconformity, if
requested to do so. Subject to the limitations in Sections 5.1, 5.2.4, 5.3.1,
5.3.2 and 5.3.3, MPI agrees to replace, at no additional expense to CI, such
nonconforming Licensed

                                                                              12
<PAGE>   13

Materials or Non-Proprietary Materials with conforming product within thirty
(30) days after receipt of CI's notification under this Section 5.3.

                  5.3.7 In the event that MPI disputes CI's evidence of
nonconformity, MPI may, at its own expense, request that an independent third
party tester selected by the parties analyze any unit of Licensed Materials or
Non-Proprietary Materials rejected by or on behalf of CI for nonconformity and,
if the independent third party tester determines that any such unit of Licensed
Materials or Non-Proprietary Materials was conforming, then CI shall be
responsible for payment of such units and for such analysis.

                  5.3.8 All returns of Licensed Materials and Non-Proprietary
Materials shall be in accordance with a mutually agreeable product return
protocol.

         5.4 Allocation. In the event that MPI is unable (due to force majeure
or otherwise) to supply both MPI's worldwide requirements of Licensed Materials
or Non-Proprietary Materials, and quantities of such Materials forecast pursuant
to Section 5.2.1 and ordered by CI under Section 5.2.2 above, MPI shall allocate
the quantities of such Licensed Materials or Non-Proprietary that MPI has in
inventory, and that MPI is able to produce, so that CI receives at least its
proportional share of available supplies as determined based on reasonable
forecasts of the requirements of CI, MPI and other third parties (taking into
consideration past requirements for such Materials relative to past forecasts).

         5.5 Compliance with Regulatory Agency Requirements. MPI shall comply
with all laws and regulations applicable to the manufacture of Licensed
Materials and Non-Proprietary Materials. Upon CI's prior written approval, such
approval not to be unreasonably withheld, CI shall reimburse MPI up to $400 for
each low volume exemption ("LVE") filing required for non-research use, in
performance of MPI's obligations hereunder. Non-Proprietary Materials for which
such non-research use is intended shall be identified by CI prior to such
non-research use, for determination of such LVE filing requirement and for
inclusion in Exhibit C attached hereto.

                                    ARTICLE 6
              OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

         6.1 Patent Prosecution. MPI shall control, at its sole expense, the
prosecution and maintenance activities pertaining to MPI Patents, using counsel
of its choice and in such countries as it deems appropriate.

         6.2 Patent Marking. CI shall use reasonable efforts to mark
advertisements, labels, and product literature that pertain to Finished Products
to mention the patent number of MPI Patents or a statement of pending patent
status, and a statement to the effect that Licensed Materials are limited to use
in the Field only.

         6.3 Patent Enforcement. If either party reasonably believes that any
MPI Technology Package is infringed or misappropriated by a third party or is
subject to a declaratory judgement action arising from such infringement, such
party shall promptly notify the other party. Both parties shall use their best
efforts in cooperating with each other to terminate such infringement or

                                                                              13
<PAGE>   14

misappropriation without litigation. If such efforts without litigation are
unsuccessful, prosecution of a third party for the infringing use of MPI's
Technology Package may be undertaken.

                  6.3.1 MPI Initiating Enforcement Actions. MPI shall have the
initial right (but not the obligation) to enjoin such misappropriation, to
enforce the MPI Patents with respect to such infringement, or to defend any
declaratory judgment with respect to the MPI Technology Package (for purposes of
this Section 6.3, any such action is herein after referred to as an "Enforcement
Action"). MPI shall keep CI reasonably informed of the progress of any such
Enforcement Action, and CI shall have the right to participate with counsel of
its own choice at its own expense.

                  6.3.2 CI Initiating Enforcement Actions. In the event that MPI
fails to initiate an Enforcement Action to protect MPI Technical Information or
to enforce the MPI Patents against a commercially significant infringement by a
third party, which infringement or misappropriation consists of the manufacture,
Sale or use of a product in the Field, within one hundred twenty (120) days of a
request by CI to initiate such Enforcement Action, CI may initiate an
Enforcement Action against such infringement with MPI's prior written approval,
which approval shall not be unreasonably withheld or delayed, and at CI's
expense. MPI's approval for initiation of an Enforcement Action notwithstanding,
CI shall not enter into any settlement of an Enforcement Action initiated by CI,
if such settlement admits the unpatentability, invalidity or unenforceability of
any MPI Patent without the written consent of MPI.

                  6.3.3 Recoveries. If a party undertakes an Enforcement Action
at its own expense, it shall be entitled to 100% of the recoveries therefrom. If
the other party chooses to join such Enforcement Action at its own expense, the
parties shall agree in advance what the apportionment of expenses and recoveries
shall be.

         6.4 Defensive Actions. If a claim, suit or proceeding (any for purposes
of this Section 6.4, an "Action") is brought against CI or MPI (the "Subject
Party") and such Action is directed to the subject of a patent or patent
application within the MPI Patents, the Subject Party shall promptly notify the
other party. As between the parties to this Agreement, the Subject Party shall
be entitled to control the defense in any such action(s); provided that the
other party shall have the right to participate in the defense or settlement
thereof at its own expense with counsel of its own choosing. Except as agreed in
writing by the other party, the Subject Party shall not enter into any
settlement of an Action, if such settlement admits the unpatentability,
invalidity or unenforceability of any MPI Patent. The Subject Party agrees to
keep the other party hereto reasonably informed of all material developments in
connection with any Action.

         6.5 MPI Trademarks. CI shall use trademarks of MPI to identify Licensed
Materials that are supplied by MPI. CI shall not use MPI's trademarks to
identify Licensed Materials if such Licensed Materials contain no components
that are supplied by MPI and CI shall not use any other of MPI's trademarks,
trade names, slogans, logos, or packaging designs (or any similar trademarks,
trade names, slogans, logos, or packaging designs), except where such use is
specifically authorized in writing by MPI in advance.

                                                                              14
<PAGE>   15

                  6.5.1 CI shall properly use all such trademarks and shall
acknowledge MPI's ownership of such trademark(s) in advertisements,
publications, and product literature. Where space is available, product labels
shall acknowledge MPI's ownership of such trademarks.

                  6.5.2 CI shall not register nor assist a third party to
register any of MPI's trademarks, trade names, slogans, logos, or packaging
designs (or any similar trademarks, trade names, slogans, logos, or packaging
designs) except as specifically authorized in writing by MPI in advance.

         6.6 Reservation. Other provisions of this Article 6 notwithstanding, in
the event that any third party shall file an infringement suit against either
party, where the suit alleges that a Finished Product or Service, only when used
as offered for Sale by CI, infringes the patent of such third party, (i.e. it is
the particular method of use offered by CI that is the issue, rather than the
materials furnished by MPI); then CI shall have the option to discontinue such
use or to indemnify and hold MPI harmless from and against all proceedings and
claims by third parties arising out of the use or sale of Finished Products or
Services in the allegedly infringing manner. Where the suit alleges that it is a
Licensed Material that infringes the patent of such third party, MPI shall have
the option to waive its exclusive right to the manufacture of such Licensed
Material in accordance with Section 5.1.8 above, but not to otherwise limit the
access of CI to such Licensed Material.

                                    ARTICLE 7
                         REPRESENTATIONS AND WARRANTIES

         7.1 MPI Warranties. MPI hereby represents, warrants and covenants to CI
that (i) it has the full right and authority to enter into this Agreement and
grant the rights and licenses granted herein; (ii) it has not previously granted
and will not grant any rights in conflict with the rights and licenses granted
herein; (iii) to MPI's knowledge and belief, MPI is not aware of any third party
intellectual property rights that are infringed by Licensed Materials, and there
are no existing or threatened actions, suits or claims pending against it with
respect to its right to enter into and perform its obligations under this
Agreement; and (iv) to MPI's knowledge and belief, the Licensed Materials are
useful for the methods described or claimed in MPI Patents, but MPI MAKES NO
WARRANTIES OR REPRESENTATIONS OF MERCHANTABILITY OR SUITABILITY FOR A PARTICULAR
PURPOSE.

         7.2 CI Warranties. CI hereby represents, warrants and covenants that it
has the full right and authority to enter into this Agreement.

                                    ARTICLE 8
                                 CONFIDENTIALITY

         8.1 Confidential Information. Except as expressly provided herein, the
parties agree that, for the term of this Agreement and for five (5) years
thereafter, the receiving party shall not publish or otherwise disclose and
shall not use for any purpose any information furnished to it by the other party
hereto pursuant to this Agreement which if disclosed in tangible form is marked
"confidential" or with other similar designation to indicate its confidential or
proprietary nature, or if disclosed

                                                                              15
<PAGE>   16

orally is confirmed as confidential (any oral disclosures must be identified in
writing as confidential within (30) thirty days of such disclosure) or
proprietary by the party disclosing such information at the time of such
disclosure (collectively, "Confidential Information"). Notwithstanding the
foregoing, it is understood and agreed that Confidential Information shall not
include information that, in each case as demonstrated by written documentation:

                  8.1.1 was already known to the receiving party, other than
under an obligation of confidentiality, at the time of disclosure;

                  8.1.2 was generally available to the public or otherwise part
of the public domain at the time of its disclosure to the receiving party;

                  8.1.3 became generally available to the public or otherwise
part of the public domain after its disclosure and other than through any act or
omission of the receiving party in breach of this Agreement; or

                  8.1.4 was subsequently lawfully disclosed to the receiving
party by a person other than a party hereto or developed by the receiving party
without reference to any information or materials disclosed by the disclosing
party.

                  8.1.5 Sections 8.1.1 through 8.1.4 notwithstanding,
information disclosed by one party to another shall still be deemed Confidential
Information of the disclosing party subject to the protection of this Section
8.1 if such disclosed information is

                           (i) a specific embodiment that is only generally
described by information in the public domain or the receiving party's
possession or

                           (ii) a combination that can be pieced together and
reconstructed from multiple sources, none of which shows the whole combination
of materials, its principle of operation, and method of use.

         8.2 Permitted Disclosures. Notwithstanding the provisions of Section
8.1 above, each party hereto may use and disclose the other's Confidential
Information to the extent such use and disclosure is reasonably necessary, in
defending litigation, complying with applicable governmental regulations,
submitting information to tax or other governmental authorities or in exercising
its rights hereunder, provided that if a party is legally required to make any
such disclosure of the other party's Confidential Information, to the extent it
may legally do so, it will give reasonable advance written notice to the latter
party of such disclosure and, save to the extent inappropriate in the case of
patent applications, will use its reasonable efforts to secure confidential
treatment of such Confidential Information prior to its disclosure (whether
through protective orders or otherwise).

                                    ARTICLE 9
                                 INDEMNIFICATION

         9.1 Indemnification of CI. MPI shall indemnify each of CI and its
directors, officers and employees and the successors and assigns (only as
authorized under Section 11.7) of the foregoing

                                                                              16
<PAGE>   17

(collectively, the "CI Indemnitees"), and hold each CI Indemnitee harmless from
and against any and all liabilities, damages, settlements, claims, actions,
suits, penalties, fines, costs or expenses (including, without limitation,
reasonable attorneys' fees and other expenses of litigation) incurred by any CI
Indemnitee arising from or occurring as a result of any claim, action, suit, or
other proceeding brought by third parties against a CI Indemnitee arising from
or occurring as a result of the gross negligence or willful tortious misconduct
of a MPI Indemnitee.

         9.2 Indemnification of MPI. CI shall indemnify each of MPI and its
directors, officers and employees and the successors and assigns of the
foregoing (collectively, the "MPI Indemnitees"), and hold each MPI Indemnitee
harmless from and against any and all liabilities, damages, settlements, claims,
actions, suits, penalties, fines, costs or expenses (including, without
limitation, reasonable attorneys' fees and other expenses of litigation)
incurred by any MPI Indemnitee arising from or occurring as a result any claim,
action, suit, or other proceeding brought by third parties against a MPI
Indemnitee arising from or occurring as a result of the gross negligence or
willful tortious misconduct of a CI Indemnitee.

         9.3 Procedure. A party (for purposes of this Section 9.3, the
"Indemnitee") that intends to claim indemnification under any provision of this
Agreement shall: (i) promptly notify the indemnifying party (the "Indemnitor")
in writing of any claim, action, suit, or other proceeding brought by third
parties in respect of which the Indemnitee, or their directors, officers,
employees, successors or assigns intend to claim such indemnification hereunder;
(ii) provide the Indemnitor sole control of the defense and/or settlement
thereof, and (iii) provide the Indemnitor, at the Indemnitor's request and
expense, with reasonable assistance and full information with respect thereto.
Notwithstanding the foregoing, the indemnity obligation in this Article 9 shall
not apply to amounts paid in settlement of any loss, claim, damage, liability or
action if such settlement is effected without the consent of the Indemnitor, to
the extent such consent is not withheld unreasonably or delayed. Without
limiting the foregoing provisions of this Section 9.3, the Indemnitor shall keep
the Indemnitee reasonably informed of the progress of any claim, suit or
proceeding under this Section 9.3 and the Indemnitee shall have the right to
participate in any such claim, suit or proceeding with counsel of its choosing
at its own expense.

                                   ARTICLE 10
                              TERM AND TERMINATION

         10.1 Agreement Term. This Agreement shall become effective as of the
Effective Date and shall continue in full force and effect until the expiration,
revocation or invalidation of the last issued patent within the MPI Patents
("Term").

                                                                              17
<PAGE>   18

         10.2 Effect of Expiration.

                  10.2.1 Accrued Obligations. Expiration of this Agreement for
any reason shall not release either party hereto from any liability which, at
the time of such expiration, has already accrued to the other party or which is
attributable to a period prior to such expiration nor preclude either party from
pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement.

         10.3 Termination.

                  10.3.1 In the event of a material breach of a party of its
obligations hereunder, the nonbreaching party shall be entitled to terminate
this Agreement upon written notice to the breaching party, if such breach is not
cured within thirty (30) days after written notice is given by the nonbreaching
party to the breaching party specifying the breach.

                  10.3.2 In the event that CI terminates its rights to all MPI
Technology Packages pursuant to Section 2.6, CI may terminate this Agreement
upon sixty (60) days written notice to MPI.

         10.4 Effect of Termination.

                  10.4.1 Accrued Obligations. Termination of this Agreement for
any reason shall not release either party hereto from any liability which, at
the time of such termination, has already accrued to the other party or which is
attributable to a period prior to such termination nor preclude either party
from pursuing all rights and remedies it may have available hereunder or at law
or equity with respect to any breach hereunder.

                  10.4.2 Return of Materials. Upon any termination of this
Agreement, CI and MPI shall promptly return to the other party all Confidential
Information received from the other party (except one copy which may be retained
for archival purposes only).

         10.5 Survival. Sections 5.3, 10.2, 10.4, 11.1 and 11.6, and Articles
6,7,8 and 9 shall survive the expiration or termination of this Agreement for
any reason.

                                   ARTICLE 11
                                  MISCELLANEOUS

         11.1 Governing Law. This Agreement and any dispute arising from the
performance or breach hereof shall be governed by and construed and enforced in
accordance with, the laws of the State of New York, without reference to
conflicts of laws principles.

         11.2 Force Majeure. Nonperformance of any party (except for payment of
amounts due hereunder, and as provided in Section 5.1.9) shall be excused to the
extent that performance is rendered impossible by strike, fire, earthquake,
flood, governmental acts or orders or restrictions, or any other reason,
including failure of suppliers, where failure to perform is beyond the
reasonable

                                                                              18
<PAGE>   19

control of the nonperforming party. Without limiting the foregoing, the party
subject to such inability shall use reasonable efforts to minimize the duration
of any force majeure event.

         11.3 No Implied Waivers; Rights Cumulative. No failure on the part of
MPI or CI to exercise and no delay in exercising any right under this Agreement,
or provided by statute or at law or in equity or otherwise, shall impair,
prejudice or constitute a waiver of any such right, nor shall any partial
exercise of any such right preclude any other or further exercise thereof or the
exercise of any other right.

         11.4 Independent Contractors. Nothing contained in this Agreement is
intended implicitly, or is to be construed, to constitute MPI or CI as partners
in the legal sense. No party hereto shall have any express or implied right or
authority to assume or create any obligations on behalf of or in the name of any
other party or to bind any other party to any contract, agreement or undertaking
with any third party.

         11.5 Notices. All notices, requests and other communications hereunder
shall be in writing and shall be personally delivered or sent by registered or
certified mail, return receipt requested, postage prepaid; facsimile
transmission (receipt verified); or express courier service (signature
required), in each case to the respective address or fax number specified below,
or such other address or fax number as may be specified in writing to the other
parties hereto:

                  CI:   Cellomics, Inc.
                        635 William Pitt Way
                        Pittsburgh, PA 15238
                        Attn: Intellectual Property Manager
                        Fax: (412) 826-3895

                  MPI:  Molecular Probes, Inc.
                        P.O. Box 22010
                        Eugene, OR 97402-0469
                        Attn: Legal Department
                        Fax: (541) 344-6504

         11.6 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE
OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES
(INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME),
ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED
ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED
REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF
SAME.

         11.7 Assignment. This Agreement shall not be assignable by either party
to any third party except that CI may assign this Agreement to an entity that
acquires substantially all of its business or assets, whether by merger,
transfer of assets, or otherwise ("Acquisition");  [*]

     "CONFIDENTIAL [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT
OF 1933, AS AMENDED."

                                                                              19
<PAGE>   20

         11.8 Modification. No amendment or modification of any provision of
this Agreement shall be effective unless in writing signed by both parties
hereto. No provision of this Agreement shall be varied, contradicted or
explained by any oral agreement, course of dealing or performance or any other
matter not set forth in an agreement in writing and signed by both parties
hereto.

         11.9 Severability. If any provision hereof should be held invalid,
illegal or unenforceable in any jurisdiction, the parties shall negotiate in
good faith a valid, legal and enforceable substitute provision that most nearly
reflects the original intent of the parties and all other provisions hereof
shall remain in full force and effect in such jurisdiction and shall be
liberally construed in order to carry out the intentions of the parties hereto
as nearly as may be possible. Such invalidity, illegality or unenforceability
shall not affect the validity, legality or enforceability of such provision in
any other jurisdiction.

         11.10 Confidential Terms. Except as expressly provided herein, each
party agrees not to disclose any terms of this Agreement to any third party
without the consent of the other party, except as required by securities or
other applicable laws, to prospective and other investors and such party's
accountants, attorneys and other professional advisors.

         11.11 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, and all of which
together, shall constitute one and the same instrument.

         11.12 Headings. Headings used herein are for convenience only and shall
not in any way affect the construction of or be taken into consideration in
interpreting this Agreement.

         11.13 Entire Agreement. This Agreement (including the Exhibits hereto,
incorporated herein by reference) constitute the entire agreement, both written
or oral, with respect to the subject matter hereof, and supersede all prior or
contemporaneous understandings or agreements, whether written or oral, between
MPI and CI with respect to such subject matter.

[signature block next page]

###

###

                                                                              20
<PAGE>   21

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed and delivered in duplicate originals as of the date first above
written.

MOLECULAR PROBES, INC.

By: /s/ Rosaria P. Haugland
    ---------------------------
Name:  Rosaria P. Haugland
       ------------------------
Title: Vice President
       ------------------------

CELLOMICS, INC.

By: /s/ D. Lansing Taylor
    ---------------------------
Name:  D. Lansing Taylor
       ------------------------
Title: President & CEO
       ------------------------<PAGE>   1

                                                                    Exhibit 10.4

                                   AGREEMENT

         THIS AGREEMENT is made as of the 1st day of October, 1998, by and
between CELLOMICS, INC., a Pennsylvania corporation (hereinafter called
"Company") and D. LANSING TAYLOR (hereinafter "Executive").

         Company is engaged in the business of creating and selling products for
multicolor fluorescence microscopy applications and drug discovery (hereinafter
called "Company's Business").

         Executive has extensive experience in the Company's Business and
related fields.

         Company desires to employ Executive and Executive desires to remain an
employee of the Company on the terms hereinafter set forth.

         Now, therefore, intending to be legally bound hereby, the parties
covenant, promise and agree as follows:

                                   EMPLOYMENT

         1.01 Executive currently occupies and hereby agrees to remain in the
position of President and Chief Executive Officer of the Company and shall
report to the Company's Board of Directors ("Board"). Executive shall render
such business and professional services in the performance of his duties as
shall be assigned to him by the Board and which are reasonably consistent with
the position held by Executive.

         1.02 Executive shall execute his duties effectively and faithfully on a
full-time basis. Executive shall not serve as a director, employee, consultant
or advisor to any other corporation or other business enterprise without prior
written consent of the Board. Notwithstanding the foregoing, Executive shall be
permitted reasonable time to serve on scientific advisory boards for other
businesses not in competition with the Company and to honor commitments to
Carnegie Mellon University ("CMU"), the National Academy of Sciences, and
similar entities, such time not to exceed eight (8) hours per month, subject
always to the non-disclosure of information and non-competition provisions of
Article 4 hereof.

<PAGE>   2

                                      TERM

         2.01 Executive shall be employed for a period of three (3) years
commencing October 1, 1998 and ending September 30, 2001.

         2.02 Executive may terminate this Agreement without cause, upon six (6)
months written notice to the company.

         2.03 Company may immediately terminate this Agreement for "cause", upon
written notice to Executive. For the purposes of this Agreement, "cause" means
that (i) Executive has been found guilty of a felony by a court of competent
jurisdiction, (ii) Executive has committed an act of embezzlement, fraud or
theft with respect to the property of the Company, or (iii) Executive has
materially breached his obligations hereunder or has engaged in a consistent
pattern of material neglect of his duties to the Company. In such event his
compensation shall cease on the date of termination.

         2.04 Company may terminate this Agreement at any time without cause
upon written notice to Executive. In the event of such termination, Executive,
in addition to receiving all salary, bonuses and fringe benefits through the
date of notice, shall receive twelve (12) months' salary, payable monthly
following the effective date of his termination, plus full and immediate vesting
of all stock options set forth in Section 3.06 below, except those options
contingent upon the occurrence of a Transaction.

         2.05 Death or permanent total disability of Executive shall be treated
as a termination by the Company without cause.

                                  COMPENSATION

         3.01 Executive's salary shall be set for the first year of this
Agreement and may be increased during the term of this Agreement based upon
annual reviews, as determined by the Board in its sole discretion.

         3.02 Executive shall be paid a salary of Two Hundred Fifty-Five
Thousand ($255,000) Dollars per year for the first year of this Agreement, which
shall be paid to him at the company's normal payroll intervals, subject to
normal payroll deductions.

         3.03 Dependent upon his first year annual review, it is contemplated
that Executive will be paid a salary of Two Hundred Sixty Thousand ($260,000)
Dollars per year for the

                                       2
<PAGE>   3

second year of this Agreement, which shall be paid to him at the company's
normal payroll intervals, subject to normal payroll deductions.

         3.04 Dependent upon his second year annual review, it is contemplated
that Executive will be paid a salary of Two Hundred Seventy Thousand ($270,000)
Dollars per year for the third year of this Agreement, which shall be paid to
him at the company's normal payroll intervals, subject to normal payroll
deductions.

         3.05 In addition to the annual base salaries payable to Executive
pursuant to Sections 3.01, 3.02 and 3.03 hereof, Executive shall be entitled to
incentive compensation, up to a maximum amount of twenty (20%) percent of his
salary, in accordance with a formula as agreed upon in each year of this
Agreement with the Board of Directors. Executive and the Board of Directors will
mutually agree upon the formula for attainment of the incentive compensation no
later than November 30 in each year of the Agreement. The formula for the first
year of this Agreement is attached hereto as Exhibit "A".

         3.06 In addition to the annual base salaries payable to Executive
pursuant to Sections 3.01, 3.02 and 3.03 hereof and the incentive compensation
pursuant to Section 3.05 hereof, Executive shall be entitled to non-qualified
stock options pursuant to the provisions of the Cellomics, Inc. Stock Plan.
Executive shall be entitled to purchase twenty thousand (20,000) shares of the
Company's common capital stock immediately at its current option price of
56 cents per share. Thirty thousand (30,000) additional Stock Options shall be
granted hereunder subject to a three (3) year vesting period that commences on
the date of this Agreement. Ten thousand (10,0000) options shall vest on each
anniversary of the date of this Agreement, such that the final 10,000 options
shall vest on October 1, 2002. Any such exercise may be made only to the extent
of the number of shares which were purchasable on the date of such termination
of employment. If Executive dies during such three (3) month period, any
unexercised options shall be exercisable by Executive's personal
representatives, heirs or legatees to the same extent and during the same period
that Executive could have exercised such options on the date of his death.

         In the event of a reorganization, merger or consolidation in which the
Company is not the surviving entity, or the liquidation, dissolution or sale of
substantially all of the assets of the Company (each a "Transaction"), during
the calendar year 1999, Executive shall be granted additional options fully
vested at the current option price of 56 cents. If the cash or stock
consideration paid in the Transaction exceeds $75,000,000 dollars Executive will
be entitled to an additional 20,000 options for a total of 40,000 options. If
the cash or stock consideration paid in the Transaction exceeds $95,000,000
dollars Executive shall be entitled to 15,000 additional options or a total of
65,000 options.

                                       3
<PAGE>   4

         In the event of a transaction after calendar year 1999, the Company, or
the entity assuming the obligations of the Company, shall, as to any Stock
Options granted but not yet exercised under this Agreement, either (i) make
appropriate provision for the protection of such Stock Options by the
substitution on an equitable basis of appropriate securities of the Company or
of the merged, consolidated, reorganized, or other successor entity which will
be issuable in respect of the shares of Common Stock of the Company, provided
that the excess of the aggregate Fair Market Value of the securities subject to
the Stock Options immediately after such substitution over the purchase price
thereof is not more than the excess of the aggregate Fair Market Value of the
shares subject to such Stock Options immediately before such substitution over
the purchase price thereof, (ii) upon written notice to the Optionee, provide
that all unexercised Stock Options (including, without limitation, those which
would, but for this Section 6.1, not yet be exercisable) must be exercised
within a specified number of days from the date of such notice or such Stock
Options will be terminated, or (iii) upon written notice to the Optionee,
provide that the Company or the merged, consolidated, reorganized, or other
successor entity shall have the right, upon the effective date of any such
Transaction, to purchase all unexercised Stock Options at an amount equal to the
aggregate Fair Market Value on such date of the shares subject to such Stock
Options less the aggregate purchase price therefor, such amount to be paid in
cash or, if securities of the merged, consolidated, reorganized, or other
successor entity are issuable in respect of the shares of the Common Stock or
assets of the Company, then, in the discretion of the Company, in securities of
such merged, consolidated, reorganized, or other successor entity equal in Fair
Market Value to the aforesaid amount. In any such case the Company shall, in
good faith, determine Fair Market Value and may, in its discretion, advance the
lapse of any installment periods and exercise dates.

         3.07 In addition to the annual base salaries pursuant to Sections 3.02,
3.03 and 3.04, the incentive compensation pursuant to Section 3.05, and the
stock options pursuant to Section 3.06, Company will provide Executive with
fringe benefits in the aggregate not less favorable than those provided to other
executives of Company who hold comparable positions.

                   CONFIDENTIAL INFORMATION, NON-COMPETITION,
                          AND ASSIGNMENT OF INVENTIONS

         4.01 Executive acknowledges that the Company's business is a
specialized business which has the potential to be marketed worldwide, and which
will involve proprietary research, product and marketing information and that
his agreement to the terms of this Section is an important consideration in the
Company's decision to continue to employ him.

                                       4
<PAGE>   5

         4.02 The Company recognizes that Executive brings with him a great deal
of knowledge in the field of the Company's Business which is not the subject of
any restrictions imposed by this Agreement except the non-competition provision
hereafter set forth.

         4.03 Executive agrees to keep secret all confidential information
relating to the Company's business or that of any present or future affiliated
company, including without limitation, proprietary research and development
information, marketing studies and plans, cost information, customer lists and
other confidential business affairs, developed by or for the Company before or
after the commencement of the term of this Agreement, and not to disclose the
same to anyone inside or outside of the Company who has not executed a non-
disclosure agreement with the Company, and to disclose in the course of
performing his duties for the Company.

         Upon request by the Company, Executive agrees to promptly return to the
company at the termination of his employment or any time thereafter upon
request, all Company or affiliated organizations' documents and information, in
any and all media, and all copies thereof which he may have acquired during his
term of employment with the Company or which he thereafter acquired without
authorization from the Company.

         4.04 (a) Executive agrees that he will promptly make full written
disclosure to the Company, will hold in trust for the sole right and benefit of
the Company, and hereby assigns to the Company, or its designee, all of his
right, title and interest in and to any and all inventions, original works of
authorship, developments, concepts, improvements or trade secrets, whether or
not patentable or registerable under copyright or similar laws, which he may
solely or jointly conceive or develop or reduce to practice, or cause to be
conceived or developed or reduced to practice, during the period of time he is
in the employ of the Company (collectively referred to as "Inventions").
Executive further acknowledges that all original works of authorship which are
made by him (solely or jointly with others) within the scope of and during the
period of his employment with the Company and which are protectable by copyright
are "works made for hire" as that term is defined in the United States Copyright
Act.

         (b) Executive agrees to assign to the United States government all of
his right, title and interest in and to any and all Inventions whenever such
full title is required to be in the United States by a contract between the
Company and the United States or any of its agencies.

         (c) Executive agrees to keep and maintain adequate and current written
records of all Inventions made by him (solely or jointly with others) during the
term of his employment with the Company. The records will be in the form of
notes, sketches, drawings

                                       5
<PAGE>   6

and any other format that may be specified by the Company. The records will be
available to and remain the sole property of the Company at all times.

         (d) Executive agrees to assist the Company, or its designee, at the
Company's expense, in every proper way to secure the Company's rights in the
Inventions and any copyrights, patents, mask work rights or other intellectual
property rights relating thereto in any and all countries, including the
disclosure to the Company of all pertinent information and data with respect
thereto, the execution of all applications, specifications, oaths, assignments
and all other instruments which the Company shall deem necessary in order to
apply for and obtain such rights and in order to assign and convey to the
Company, its successors, assigns and nominees, the sole and exclusive rights,
title and interest in and to such Inventions, and any copyrights, patents, mask
work rights or other intellectual property rights relating thereto. Executive
further agrees that his obligation to execute or cause to be executed, when it
is in his power to do so, any such instrument or papers shall continue after the
termination of this Agreement. If the Company is unable, because of Executive's
mental or physical incapacity or for any other reason, to secure his signature
to apply for or to pursue any application for any United States or foreign
patents or copyright registrations covering Inventions or original works of
authorship assigned to the Company as above, then Executive hereby irrevocably
designates and appoints the Company and its duly authorized officers and agents
as his agent and attorney-in-fact, to act for and in his behalf and stead to
execute and file any such applications and to do all other lawfully permitted
acts to further the prosecution and issuance of letters patent or copyright
registrations thereon with the same legal force and effect as if executed by
Executive.

         4.05 (a) Executive agrees that during his employment by the Company and
for a period of eighteen (18) months after the termination thereof regardless of
the basis upon which it is terminated, he will not in any place in the world,
directly or indirectly, (a) engage in any of the businesses actively conducted
by the Company on the date of the termination of his employment, or (b) any
business which, to his knowledge, had been under development by the Company as a
potential future business for the Company.

         (b) In the event Executive leaves the employ of the Company, he hereby
grants consent to notification by the Company to his new employer about his
rights and obligations under this Agreement.

         (c) Executive agrees that for a period of twelve (12) months
immediately following the termination of his relationship with the Company for
any reason, he shall not either directly or indirectly solicit, induce, recruit
or encourage any of the Company's employees to leave their employment, or take
away such employees, or attempt to solicit,

                                       6
<PAGE>   7

induce, recruit, encourage or take away employees of the Company, either for
himself or for any other person or entity.

         4.06 If Executive commits a material breach of this Article 4, he shall
forfeit all rights to receive any future amounts of any nature whatsoever from
the Company under this Agreement, excluding vested stock options. Executive
further agrees that the provisions of this Article 4 may be specifically
enforced by a court of competent jurisdiction, it being acknowledged by
Executive that any such material breach will cause irreparable harm to the
Company, and that money damages will not provide an adequate remedy to the
Company. Such rights and remedies shall be in addition to and not in lieu of any
other rights that the Company may have in law or in equity.

                              CONFLICT OF INTEREST

         5.01 Executive agrees to diligently adhere to the Conflict of Interest
Guidelines attached hereto as Exhibit "B".

                                 MISCELLANEOUS

         6.01 All notices in connection with this Agreement shall be in writing
and shall be deemed to have been given:

                  i.       at the time delivered to the recipient;

                  ii.      with respect to telecopies, at the time of electronic
                           confirmation by the recipient; or

                  iii.     four (4) days after deposit at any general or branch
                           United States Post Office, enclosed in an envelope
                           marked Certified or Registered Mail, Return Receipt
                           Requested, postage prepaid, addressed to the party at
                           the following address:

                           To the Company:
                           Cellomics, Inc.
                           635 William Pitt Way
                           Pittsburgh, PA 15238
                                       Att: CFO

                                       7
<PAGE>   8

                           To Executive:

                           D. Lansing Taylor
                           910 Notre Dame Place
                           Pittsburgh, PA 15215

                           or at such other address as the parties provide to
                           each other by written notice.

         6.02 This Agreement may be modified only in writing signed by Executive
and the Chairman of the Board of Directors of the Company. No waiver by either
party of any breach by the other or any condition or provision of this Agreement
to be performed by the other party shall be a waiver of similar or dissimilar
performance, provisions or conditions at the same or at any future time.

         6.03 This Agreement constitutes the entire Agreement relating to the
employment of Executive by the Company, and supersedes all prior agreements and
understandings, whether written or oral, related thereto.

         6.04 The parties represent to each other that this Agreement is not
contrary to any other agreement or understanding that applies to them and that
this will be a valid and binding obligation. The parties agree to execute such
documents and take such further action as may be necessary to implement the
intent of this Agreement.

         6.05 This Agreement may not be assigned by Executive to any other
person or entity. The Company's rights and obligations hereunder shall inure to
and be binding upon the successors and assigns of the Company, but may not be
assigned by the Company without Executive's consent, except in connection with
the sale or other transfer of substantially all of the Company's business.

         6.06 The validity, interpretation, construction, performance and
enforcement of this Agreement shall be governed by the internal laws of the
Commonwealth of Pennsylvania without application of conflicts of law.

         6.07 The invalidity or unenforceability of any term of this Agreement
shall not invalidate or affect any other term of this Agreement.

         6.08 Any and all disputes arising from this Agreement or from
Executive's employment relationship, with the exception of the equitable
remedies set forth in Section 4.05 hereof, with Company shall be resolved by
binding arbitration in Pittsburgh,

                                       8
<PAGE>   9

Pennsylvania, in accordance with the Employment Dispute Resolution Rules of the
American Arbitration Association.

         6.09 This Agreement may be executed in counterparts, each of which
shall be deemed to be an original.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement
this 8 day of M, 1999.

Attest:                                 CELLOMICS, INC.

/s/ YVONNE PATRICIA CLARKE CHANCE           By: /s/ ???
---------------------------------             -------------------------------

Title: NOTARY PUBLIC                    Title: DIRECTOR
      --------------------------              ----------------------------
       MY COMMISSION EXPIRES
       OCTOBER 31, 1999

Witness:                                EXECUTIVE

/s/ ISAURA GONZALEZ                     /s/ D. Lansing Taylor
--------------------------------        ----------------------------------
ISAURA GONZALEZ                         D. Lansing Taylor

                                       9
<PAGE>   10

                                  EXHIBIT "A"

                            OBJECTIVES FOR CEO BONUS

1.   Hire 4 VPs and a COO                                     30%

2.   Meet milestones for 2nd takedown                         30%

3.   Meet 80% of revenue forecast and not exceed              25%
     105% of costs in plan

4.   Complete 1 major corporate partnering deal               15%
                                                             ----
                                                             100%
                                                             ====

<PAGE>   11

                                  EXHIBIT "B"

                        CONFLICT OF INTEREST GUIDELINES

         It is the policy of Cellomics, Inc. to conduct its affairs in strict
compliance with the letter and spirit of the law and to adhere to the highest
principles of business ethics. Accordingly, all officers, employees and
independent contractors must avoid activities which are in conflict, or give the
appearance of being in conflict, with these principles and with the interests of
the Company. The following are potentially compromising situations which must be
avoided. Any exceptions must be reported to the President and written approval
for continuation must be obtained.

         Revealing confidential information to outsiders or misusing
confidential information. Unauthorized divulging of information is a violation
of this policy whether or not for personal gain and whether or not harm to the
Company is intended. (The Employment Confidential Information and Invention
Assignment Agreement elaborates on this principle and is a binding agreement.)

         Accepting or offering substantial gifts, excessive entertainment,
favors or payments may be deemed to constitute undue influence or otherwise be
improper or embarrassing to the Company.

         Participating in civic or professional organizations that might involve
divulging confidential information of the Company.

         Initiating or approving personnel actions attaching reward or
punishment of employees or applicants where there is a family relationship or is
or appears to be a personal or social involvement.

         Initiating or approving any form of personal or social harassment of
employees.

         Investing or holding outside directorships in suppliers, customers or
competing companies, including financial speculation, where such investment or
directorship might influence in any manner a decision or course of action of the
Company.

         Borrowing from or lending to employees, customers or suppliers.

         Acquiring real estate of interest to the Company.

<PAGE>   12

         Improperly using or disclosing to the Company any proprietary
information or trade secrets or any former or concurrent employer or other
person or entity with whom obligations of confidentiality exist.

         Unlawfully discussing prices, costs, customers, sales or markets with
competing companies or their employees.

         Making any unlawful agreements with distributors with respect to
prices.

         Improperly using or authorizing the use of any inventions which are the
subject of patent claims or any other person or entity.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]